NO177794C - Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten - Google Patents

Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten

Info

Publication number: NO177794C
Authority: NO; Norway
Prior art keywords: preparation; nucleic acid; well; host cell; fusion protein
Prior art date: 1986-11-01

Application number

NO882918A

Other languages

English (en)

Other versions

NO882918D0 (no

NO882918L (no

NO177794B (no

Inventor

Alan John Kingsman

Susan Mary Kingsman

Sally Elizabeth Adams

Original Assignee

British Bio Technology

Oxford Gene Systems Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-01

Filing date

1988-06-30

Publication date

1995-11-22

1986-11-01 Priority claimed from GB868626148A external-priority patent/GB8626148D0/en

1987-04-09 Priority claimed from GB878708532A external-priority patent/GB8708532D0/en

1988-06-30 Application filed by British Bio Technology, Oxford Gene Systems Ltd filed Critical British Bio Technology

1988-06-30 Publication of NO882918D0 publication Critical patent/NO882918D0/no

1988-08-29 Publication of NO882918L publication Critical patent/NO882918L/no

1995-08-14 Publication of NO177794B publication Critical patent/NO177794B/no

1995-11-22 Publication of NO177794C publication Critical patent/NO177794C/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO882918A 1986-11-01 1988-06-30 Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten NO177794C (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB868626148A GB8626148D0 (en)	1986-11-01	1986-11-01	Antigen presentation & purification system
GB878708532A GB8708532D0 (en)	1987-04-09	1987-04-09	Particulate hybrid hiv antigens
US3688887A	1987-04-10	1987-04-10
PCT/GB1987/000763 WO1988003562A1 (en)	1986-11-01	1987-10-28	Particulate hybrid hiv antigens

Publications (4)

Publication Number	Publication Date
NO882918D0 NO882918D0 (no)	1988-06-30
NO882918L NO882918L (no)	1988-08-29
NO177794B NO177794B (no)	1995-08-14
NO177794C true NO177794C (no)	1995-11-22

Family

ID=27263195

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO882918A NO177794C (no)	1986-11-01	1988-06-30	Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten

Country Status (8)

Country	Link
EP (1)	EP0329671B1 (no)
JP (1)	JPH02501107A (no)
AU (1)	AU606627B2 (no)
DE (1)	DE3788806T2 (no)
ES (1)	ES2010230A6 (no)
HU (1)	HUT50875A (no)
NO (1)	NO177794C (no)
WO (1)	WO1988003562A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3006789A (en) *	1988-02-24	1989-08-24	Smithkline Beckman Corporation	Expression of hiv binding proteins
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) *	1988-06-10	1997-03-25	Theriod Biologics, Incorporated	Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) *	1988-06-10	1998-05-05	Therion Biologics Corporation	Self-assembled, defective, non-self-propagating lentivirus particles
EP0361749B1 (en) *	1988-09-27	1995-02-08	Dana Farber Cancer Institute	A vector comprising a replication competent HIV-I provirus and a heterologous gene
CA2003383A1 (en) *	1988-11-23	1990-05-23	Sushil G. Devare	Synthetic dna derived recombinant hiv antigens
AU4665389A (en) *	1988-11-23	1990-06-12	Regents Of The University Of California, The	Position-specific insertion vectors and method of using same
JP3034025B2 (ja) *	1989-06-01	2000-04-17	アプライド・バイオテクノロジー・インコーポレーテツド	自己アセンブルド欠損非自己増殖性ウイルス粒子
GB8923123D0 (en) *	1989-10-13	1989-11-29	Connaught Lab	A vaccine for human immunodeficiency virus
US5989886A (en) *	1991-01-02	1999-11-23	The Johns Hopkins University	Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
GB9107631D0 (en) *	1991-04-10	1991-05-29	British Bio Technology	Proteinaceous particles
AU2462392A (en) *	1992-04-14	1993-11-18	British Biotech Pharmaceuticals Limited	Induction of CTL responses
WO1994016084A1 (en) *	1993-01-16	1994-07-21	British Bio-Technology Limited	Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens
FR2703996B1 (fr) *	1993-04-16	1995-07-21	Transgene Sa	Ensemble de transposition destine au transfert d'un gene d'interet dans le genome d'une cellule eucaryote.
DE4335025A1 (de) *	1993-10-14	1995-04-20	Boehringer Ingelheim Int	Endosomolytisch wirksame Partikel
DE4405810A1 (de)	1994-02-23	1995-08-24	Behringwerke Ag	Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP0907740A1 (en) *	1997-01-02	1999-04-14	Universidade Federal De Minas Gerais	THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN HYBRID PROTEIN (p24/p17) DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUSES (HIV-1)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR76274B (no) *	1981-08-04	1984-08-04	Univ California
JP2708046B2 (ja) *	1986-11-01	1998-02-04	ブリティッシュバイオテックファーマシューティカルズリミテッド	融合タンパク質および粒子

1987
- 1987-10-28 EP EP87907014A patent/EP0329671B1/en not_active Expired - Lifetime
- 1987-10-28 WO PCT/GB1987/000763 patent/WO1988003562A1/en active IP Right Grant
- 1987-10-28 HU HU875702A patent/HUT50875A/hu unknown
- 1987-10-28 DE DE3788806T patent/DE3788806T2/de not_active Expired - Fee Related
- 1987-10-28 JP JP62506486A patent/JPH02501107A/ja active Pending
- 1987-10-28 AU AU81534/87A patent/AU606627B2/en not_active Ceased
- 1987-10-30 ES ES8703104A patent/ES2010230A6/es not_active Expired
1988
- 1988-06-30 NO NO882918A patent/NO177794C/no unknown

Also Published As

Publication number	Publication date
ES2010230A6 (es)	1989-11-01
DE3788806T2 (de)	1994-07-07
NO882918D0 (no)	1988-06-30
NO882918L (no)	1988-08-29
NO177794B (no)	1995-08-14
AU8153487A (en)	1988-06-01
WO1988003562A1 (en)	1988-05-19
EP0329671A1 (en)	1989-08-30
AU606627B2 (en)	1991-02-14
DE3788806D1 (de)	1994-02-24
HUT50875A (en)	1990-03-28
EP0329671B1 (en)	1994-01-12
JPH02501107A (ja)	1990-04-19

Similar Documents

Publication	Publication Date	Title
NO177793C (no)	1995-11-22	Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
NO177794C (no)	1995-11-22	Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
NO175715C (no)	1994-11-23	Analogifremgangsmåte ved fremstilling av terapeutisk aktive aminosyrederivater, samt mellomprodukter ved fremstilling av disse
DK110885A (da)	1985-09-13	Nucleinsyre-proteinkonjugater, disses anvendelse samt fremgangsmaade til fremstilling heraf
IT7921838A0 (it)	1979-04-13	Processo di rivelazione e di caratterizzazione di un acido nucleico o di una sua sequenza e reattivo enzimatico per la realizzazione di questo processo.
NO871785L (no)	1987-11-02	Fremgangsmaate for fremstilling av et proteinprodukt samt vektorsystem for fremgangsmaatens utfoerelse.
DK374087D0 (da)	1987-07-17	Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne
NO964445L (no)	1996-10-18	DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
NZ221790A (en)	1990-07-26	Method for the continuous production of a heterologous protein in a eukaryotic host cell
ATE158816T1 (de)	1997-10-15	Expression von pace in wirtszellen und verfahren zu dessen verwendung
DK158659C (da)	1991-01-21	2,4,6-triiod-isophthalsyrederivater, deres fremstilling og roentgenkontrastmidler indeholdende disse.
AU587989B2 (en)	1989-09-07	DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
ZA864525B (en)	1987-03-25	Vector for expression of interferon-ypsilon in mammalian cells,method for using it and product obtained
NO179109C (no)	1996-08-07	Ekspresjonsvektor, rekombinante vertsceller samt fremgangsmåte for fremstilling av terapeutisk aktivt, rekombinant CSF
DK388789D0 (da)	1989-08-08	Hybridderivat af humant protein d, dets fremstilling og anvendelse samt dna, som koder derfor, og genstruktur og vaertscelle indeholdende denne dna
IT8520036A0 (it)	1985-03-22	Processo per la preparazione biotecnologica di acidi alfa-arilalcanoici otticamente attivi.
DK534286A (da)	1987-05-10	Nicotinsyrederivater, deres fremstilling og anvendelse som herbicider samt mellemprodukter ved fremstillingen og disses fremstilling
DK124787A (da)	1987-09-13	Peptider indeholdende op til 8-aminosyregrupperinger og fysiologisk uskadelige salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter ved fremstillingen
DK354188D0 (da)	1988-06-27	Guanidinothiazolforbindelse, fremgangsmaade til d eres fremstilling samt anvendelsen heraf som mellemprodukt i famotidinprocessen
WO1994025590A3 (en)	1994-12-22	Trichohyalin and transglutaminase-3 and methods of using same
DK94385D0 (da)	1985-02-28	Proteiner, farmaceutiske praeparater, gener, vektorer, vaertsorganismer samt fremgangsmaader til deres fremstilling
NO874573D0 (no)	1987-11-03	Nucleinsyreprober for paavisning av latent humant cytomegalovirus i lodprodukter.
AU5945386A (en)	1987-01-08	Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
NO178036C (no)	1996-01-10	Fremgangsmåte for fremstilling av fusjonsproteiner, genstruktur, vektorer streptomycetceller og fusjonsproteinene
AU6521186A (en)	1987-05-19	Lytic viruses as expression vectors, host cell containing same and process for protein production